Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/all.16609 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Number of CD34 Cells Employed in Autologous Hematopoietic Stem Cell Transplantation for Persons With Multiple Sclerosis Is Not Related to the Neurological Outcome of the Procedure.
Clin Transplant
September 2025
Centro De Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico.
Free Light Chain Multiple Myeloma: Atypical Appearance on Serum Immunofixation.
Clin Lab
September 2025
Background: Light chain multiple myeloma (LCMM) is a malignant hematological disease characterized by bone marrow infiltration by tumor plasma cells and the secretion of monoclonal free light chains (κ or λ). It is often di-agnosed through hypogammaglobulinemia detected by serum protein electrophoresis, followed by immunotyping showing a monoclonal band in free light chains. However, the structure of monoclonal light chains can sometimes complicate laboratory findings.
View Article and Find Full Text PDFPotential Involvement of NINJ1-Mediated Plasma Membrane Rupture in Lytic Death of Granulosa Cells in PCOS.
Am J Reprod Immunol
September 2025
Department of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, Tokat, Turkey.
Commentary on "Complex left main bifurcation PCI in a patient with dual positivity: A unique interventional approach - A case report" by Setty et al., 2025.
Int J Surg Case Rep
September 2025
Clinical Immunology Research Center, Ali-Ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran; Department of Internal Medicine and Virology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Targeting ARPC1B Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment.
Cell Prolif
September 2025
Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, China.
ARPC1B cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy.
View Article and Find Full Text PDF